Phase 3 N=118 VA MERIT: A Comparative Efficacy Study: Treatment of Non-Healing Diabetic
Diabetic Foot Ulcer
Primary: Wound Closure by Week 15 — 10; 15; 9; 16 Participants — p=0.0517
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=517 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Percentage of Participants With Proven or Probable Invasive Fungal Infections (IFI) — 3.1; 7.2 Percentage of participants
Phase 4 N=198 Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality
Coronary Artery Disease
Primary: Coronary Artery Diameter Change — 1.14; 1.13; 1.15 Fold change
Phase 2 N=32 Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients
CD30 Positive Primary Mediastinal Large B-cell Lymphoma · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30-Positive Gray Zone Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Phase 2 N=32 Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Small Lymphocytic Lymphoma · CLL (Chronic Lymphocytic Leukemia)
Primary: Progression Free Survival Rate 2 Years After Initiation of Induction Therapy — 14; 9 Participants
Phase 3 N=453 CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris
Acne Vulgaris
Primary: Investigator Global Assessment (IGA) Success Rate up to Week 52 — 453 Participants
Phase 1 N=39 Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities
HIV Infections
Primary: Changes in Intracellular Emtricitabine Triphosphate (FTC-TP) — 0; 3380; 2580; 6470 fmol/1000000 PBMC
Phase 1 N=12 Phase I Study of GSK2982772 in Japanese Healthy Male Participants
Autoimmune Diseases
Primary: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 Participants
Phase 3 N=124 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Carcinoid Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 22; 100 Participants
Early Phase 1 N=109 Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)
Aging
Primary: Percent Change in Type 2 Myofiber Cross Sectional Area — 18.5; 14.5 Percent change
N/A N=177 Dose-Response of Gonadal Steroids and Bone Turnover in Older Men
Healthy Volunteers
Primary: Percent Change in Bone Turnover Marker (Serum C-telopeptide, CTX) — 103; 41; 29; 15 percentage change
Phase 2 N=23 Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer
Dyspnea · Non-small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Incidence of Grade 3 or Higher Hypotension, Acute Kidney Injury, Allergic Reaction, or Anaphylaxis, as Measured Using the National Cancer Institute Common Terminology…
Phase 4 N=70 Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?
Neuromuscular Block
Primary: BIS Signal Variability Using the Measured Standard Deviation During the Maintenance Phase of Anesthesia — 7.6; 7.8 units on a scale — p=0.651
Phase 2 N=254 A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma · Lymphoma, Mantle-Cell
Primary: Kaplan Meier Estimate for Progression Free Survival (PFS) by Independent Review Committee (IRC) Central Review — 37.6; 22.7 weeks — p=0.012
Phase 2 N=33 Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Acromegaly · Pituitary Gigantism
Primary: Total-group Response Rate at Month 3 — 18.2 Percentage of participants